Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

PHASE3CompletedINTERVENTIONAL
Enrollment

1,954

Participants

Timeline

Start Date

June 1, 2007

Primary Completion Date

September 1, 2011

Study Completion Date

March 1, 2016

Conditions
Acellular PertussisTetanusDiphtheria
Interventions
PROCEDURE

Taking of blood samples

No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.

BIOLOGICAL

Boostrix

A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.

BIOLOGICAL

Adacel

A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.

Trial Locations (37)

15241

GSK Investigational Site, Pittsburgh

15904

GSK Investigational Site, Johnstown

16127

GSK Investigational Site, Grove City

16505

GSK Investigational Site, Erie

20006

GSK Investigational Site, Washington D.C.

23507

GSK Investigational Site, Norfolk

27103

GSK Investigational Site, Winston-Salem

27609

GSK Investigational Site, Raleigh

28463

GSK Investigational Site, Tabor City

29412

GSK Investigational Site, Charleston

32935

GSK Investigational Site, Melbourne

33024

GSK Investigational Site, Pembroke Pines

33143

GSK Investigational Site, Miami

35802

GSK Investigational Site, Huntsville

37620

GSK Investigational Site, Bristol

40004

GSK Investigational Site, Bardstown

46601

GSK Investigational Site, South Bend

49083

GSK Investigational Site, Richland

61602

GSK Investigational Site, Peoria

63141

GSK Investigational Site, St Louis

69101

GSK Investigational Site, North Platte

72205

GSK Investigational Site, Little Rock

73112

GSK Investigational Site, Oklahoma City

77024

GSK Investigational Site, Houston

80909

GSK Investigational Site, Colorado Springs

81001

GSK Investigational Site, Pueblo

83704

GSK Investigational Site, Boise

84088

GSK Investigational Site, West Jordan

84109

GSK Investigational Site, Salt Lake City

84121

GSK Investigational Site, Salt Lake City

85014

GSK Investigational Site, Phoenix

85203

GSK Investigational Site, Mesa

85213

GSK Investigational Site, Mesa

85224

GSK Investigational Site, Chandler

85283

GSK Investigational Site, Tempe

92108

GSK Investigational Site, San Diego

92103-6204

GSK Investigational Site, San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY